JP2011168506A - Method for producing composition for oral cavity - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a method for producing an emulsion type oral cavity composition which can be produced by a simple process and has stability with time of the oral cavity composition obtained and good retention of an active ingredient thereof. <P>SOLUTION: The oral cavity composition is obtained by introducing an oil phase obtained by mixing (a) an active ingredient selected from a perfume and an agent having medicinal activity, (b) a polyhydric alcohol, (c) a (poly)glycerol fatty acid ester, (d) a nonionic surface active agent which does not fall under the (poly)glycerol fatty acid ester, and (e) an anionic surface active agent into an aqueous phase to make an emulsion. <P>COPYRIGHT: (C)2011,JPO&INPIT

Description

  The present invention relates to a method for producing an oral composition.

Conventionally, liquid oral compositions such as liquid dentifrices, mouthwashes, mouthwashes, and the like have been used as solution-type compositions, and these oral compositions are usually used as active ingredients such as bactericides and fragrances. Is blended. In addition, ethanol is blended for the purpose of assisting refreshment, improving stickiness, and improving stability over time by improving the solubility of the blended components. However, such an oral composition has problems of irritation and discomfort derived from ethanol.
In recent years, emulsion-type oral compositions have also been developed. However, emulsion-type oral compositions tend to have lower temporal stability than solution-type compositions.
For such problems, various studies have been made on the components and manufacturing processes of emulsion-type oral compositions. For example, in Patent Document 1, as a method for obtaining an oral composition that can suppress irritation derived from ethanol and has good temporal stability, an emulsion having a specific composition containing an oil component in an oil phase is separately prepared. The method of mix | blending with the composition for oral cavity containing this is proposed. In Patent Document 2, as a method for obtaining a composition for oral cavity with good appearance and stability over time, an oil phase mixed solution and an anionic surfactant aqueous solution having a specific composition containing an oily active ingredient are prepared and mixed. A method is disclosed.

JP 2005-179231 A JP 2007-197411 A

However, in the case of the methods described in Patent Documents 1 and 2, there are problems that the manufacturing process is complicated, for example, there are many blending steps. For example, when a separately prepared emulsion is blended, it is difficult to standardize the viscosity because the emulsion has a large property (viscosity) and is easily touched. Moreover, when forming an emulsion directly, the temporal composition of the oral composition obtained may not be enough.
Furthermore, the oral composition obtained by these methods may not have sufficient retention of the active ingredient in the oral cavity during use. In particular, when a fragrance is used as an active ingredient, the retention is low and the duration of flavor tends to be short.
The present invention has been made in view of the above circumstances, and an emulsion-type oral composition can be produced by a simple process, and the resulting oral composition has good temporal stability and good retention of active ingredients. An object is to provide a manufacturing method.

As a result of intensive studies, the present inventors have found that the above problem can be solved by a simple production method in which an oil phase obtained by mixing specific five components including an active ingredient is introduced into an aqueous phase. Completed.
The present invention for solving the above problems has the following aspects.
[1] An active ingredient selected from (a) a fragrance and a medicinal agent, (b) a polyhydric alcohol, (c) a (poly) glycerin fatty acid ester, and (d) a nonionic interface not corresponding to a (poly) glycerin fatty acid ester The manufacturing method of the composition for oral cavity characterized by using the oil phase formed by mixing an active agent and (e) anionic surfactant in an aqueous phase, and making it an emulsion.
[2] In the oil phase, the components (a) to (e) have a value of (c) / [(b) + (d) + (e)] / (a) of 0.01 to 4.0. The method for producing an oral composition according to [1], wherein the composition is contained at a blending ratio (mass ratio) that falls within the above range.

  ADVANTAGE OF THE INVENTION According to this invention, an emulsion type oral composition can be manufactured with a simple process, and the temporal stability of the oral composition obtained and the retention property of an active ingredient can also be provided with a favorable manufacturing method.

In the present invention, (a) an active ingredient selected from a fragrance and a medicinal agent (hereinafter referred to as (a) component), (b) a polyhydric alcohol (hereinafter referred to as (b) component), and (c) ( A poly) glycerin fatty acid ester (hereinafter referred to as component (c)), a nonionic surfactant (hereinafter referred to as component (d)) not corresponding to (d) (poly) glycerin fatty acid ester, and (e) an anionic interface. An oral phase composition is obtained by putting an oil phase obtained by mixing an active agent (hereinafter referred to as component (e)) into an aqueous phase to form an emulsion.
Specifically, a step of preparing an oil phase obtained by mixing the components (a) to (e) (oil phase preparation step), and a step of introducing the oil phase into an aqueous phase to form an emulsion (emulsification step) ) To obtain an oral composition. Hereinafter, each process will be described in more detail.

<Oil phase preparation process>
[(A) component]
The component (a) is an active ingredient selected from a fragrance and a medicinal agent.
The fragrance contains at least one fragrance component.
As a fragrance | flavor, it can select suitably from well-known fragrance | flavor and a fragrance | flavor component according to the flavor desired for the said composition for oral cavity. For example, peppermint oil, spearmint oil, anise oil, eucalyptus oil, winter green oil, cassia oil, cinnamon oil, clove oil, thyme oil, sage oil, cardamom oil, rosemary oil, marjoram oil, lemon oil, orange oil, fennel oil Natural essential oils such as nutmeg oil, lavender oil, and paracres oil; Perfume ingredients contained in the above natural essential oils such as borneol, pinene, spiranthol, etc .; ethyl acetate, ethyl butyrate, isoamyl acetate, hexanal, hexenal, methyl anthranilate, ethyl methyl phenyl glycidide , Benzaldehyde, vanillin, ethyl vanillin, furaneol, maltol, ethyl maltol, gamma / delta decalactone, gamma / deltown decalactone, N-ethyl-p-menthane-3-carboxamide, menthyl lactate, ethylene glycol-1-menthyl Perfume ingredients such as carbonates; Apple, banana, strawberry, blueberry, melon, peach, pineapple, grape, muscat, wine, cherry, squash, coffee, brandy, yogurt, etc. Formulation flavor; etc. may be mentioned, and any of these may be used alone or in combination of two or more.
A fragrance | flavor may contain a solvent (solvent for fragrance | flavors) as needed. It does not specifically limit as a solvent for fragrance | flavors, A well-known thing can be used. Specific examples include ethanol, triethyl citrate, dipropylene glycol, benzyl benzoate, and the like.

As the fragrance, a water-insoluble fragrance is particularly preferable.
“Water-insoluble” in a water-insoluble fragrance means that the solubility in water at room temperature (25 ° C.) is 30% or less. The solubility is preferably 25% or less, and more preferably 20% or less.
The solubility is determined by the following method.
First, 10 g each of water and fragrance are weighed, mixed in a 50 mL separatory funnel and allowed to stand until they are separated into two layers, then the fragrance phase and the aqueous phase are separated, the mass of the fragrance phase is measured, and before mixing The amount of decrease from the mass of the fragrance (the mass of the fragrance before mixing−the mass of the fragrance phase) is calculated, and the value (the mass decrease of the fragrance phase) is regarded as the amount dissolved in water, and is calculated from the following formula. .
Solubility = mass loss of perfume phase ÷ mass of water before mixing with perfume x 100 (%)

  As a water-insoluble fragrance | flavor, you may use the thing of desired solubility among commercially available fragrance | flavors, For example, various documents, for example, "Perfume and Flavor Chemicals", Vol. I and II, Stephen Arctander, Allured Pub. Co. (1994) and "Synthetic fragrance chemistry and commercial knowledge", Motoichi Into, Chemical Industry Daily (1996) and "Perfume and Flavor Materials of Natural Origin", Stephen Arctander, Allred Pub. Co. (1994) and “Scent of Encyclopedia”, edited by Japan Fragrance Association, Asakura Shoten (1989) and “Performerial Material Performance V.3.3”, Boelens Aroma Chemical Information Service (1996) and “Flower oil”. , Danute Lajaujis Anonis, Allured Pub. Co. (1993) or the like may be used, or any of the perfume ingredients disclosed in (1993) may be mixed to obtain a desired solubility.

A medicinal agent is a component that exerts an effective action for treating, diagnosing, preventing or alleviating pain. The medicinal agent is not particularly limited, and can be appropriately selected from known medicinal agents according to the effect desired for the oral composition (for example, bactericidal, antibacterial, anti-inflammatory, washing, vitamin supply, etc.). Specific examples include non-cationic fungicides such as triclosan and isopropylmethylphenol, cationic fungicides such as cetylpyridinium chloride, chlorhexidine hydrochloride, chlorhexidine gluconate, benzalkonium chloride and benzethonium chloride, tranexamic acid, epsilon-aminocaproic acid Anti-inflammatory agents such as dextranase, amylase, protease, mutanase, lysozyme, lytic enzyme, lytechenzyme, fluoride such as sodium fluoride, sodium monofluorophosphate, stannous fluoride, aluminum chlorohydroxy Vitamin C such as allantoin, allantoin, azulene, lysozyme chloride, ascorbic acid and derivatives thereof, α-tocophenol and derivatives thereof (for example, dl-α-tocophenol acetate), etc. Vitamin E, Vitamin B such as pyridoxine hydrochloride, sodium chloride, dihydrocholesterol, glycyrrhetin salts, glycyrrhetinic acid, hydrocholesterol, chlorophyll, copper chlorophyllin sodium, thyme, ogon, clove, hamamelis, etc. Caropeptide, sodium polyphosphate, water-soluble inorganic phosphate compound, polyvinylpyrrolidone, anticalculus agent, anti-plaque agent, potassium nitrate, aluminum lactate and the like. These medicinal agents may be used alone or in combination of two or more. Among these, non-cationic fungicides, fungicides such as cationic fungicides, anti-inflammatory agents, enzymes, and vitamin E are preferable.
As the medicinal agent, a water-insoluble one is particularly preferable. The definition of “water-insoluble” is as described in the description of the water-insoluble perfume. As the water-insoluble medicinal agent, water-insoluble fungicides such as non-cationic fungicides and cationic fungicides, water-insoluble vitamins such as vitamin E are preferable, and water-insoluble fungicides are particularly preferable. As the water-insoluble fungicide, triclosan, isopropylmethylphenol, benzalkonium chloride, benzethonium chloride and the like are preferable.

(A) As a component, both a fragrance | flavor and a medicinal agent may be mix | blended, and either one may be mix | blended. In the present invention, it is particularly preferable that at least a fragrance is included as the component (a) because the improvement in retention is remarkable and the effectiveness of the present invention is high. That is, the component (a) is preferably a fragrance or a mixture of a fragrance and a medicinal agent.
Further, as the component (a), as described above, a water-insoluble component is preferable in both cases of a fragrance and a medicinal agent. When it is water-insoluble, it is excellent in stability over time and retention of active ingredients. However, the present invention is not limited thereto, and anti-inflammatory agents such as tranexamic acid, epsilon-aminocaproic acid; enzymes such as dextranase, amylase, protease, mutanase, lysozyme, lytic enzyme, lytechenzyme; sodium fluoride, monofluoro Sodium phosphate equivalent fluoride; Azulene; Lysozyme chloride; Vitamin C such as ascorbic acid; Copper chlorophyllin sodium; Plant extracts such as Thyme, Ogon, Clove, Hamelis; Copper gluconate; Caropeptide; Sodium polyphosphate; Water-soluble materials such as inorganic phosphate compounds may be used. When the emulsion is made into an emulsion, the oil phase is dispersed in the water phase as emulsified particles. Even when the component (a) is water-soluble, the oil phase contains a surfactant (nonionic, anionic) component (a ) Component is stably present in the emulsified particles, and the same effect can be expected.
(A) 0.001-5 mass% is preferable with respect to the whole quantity (100 mass%) of compositions for oral cavity, and, as for the compounding quantity of a component, 0.001-3 mass% is more preferable, and 0.001-2 mass. % Is more preferable. If it is at least the lower limit of the range, the desired effect is sufficiently obtained and the retention is good. On the other hand, when it mixes exceeding an upper limit, there exists a possibility that the temporal stability of a composition may fall.

[Component (b)]
The component (b) is a polyhydric alcohol. The component (b) is a component that functions as a wetting agent and a stabilizer. By containing the component (b), the temporal stability of the oral composition and the retention of the active ingredient are improved.
“Alcohol” is a compound in which a hydrogen atom of a hydrocarbon is substituted with a hydroxy group, and “polyhydric alcohol” is an alcohol having two or more hydroxy groups in the molecule.
The component (b) may be a polymer such as polyglycerin, polyethylene glycol (PEG) or polypropylene glycol (PPG), or may be a non-polymer.
In the case of a polymer, the polyhydric alcohol preferably has a weight average molecular weight (Mw) of 100 to 6000, more preferably 100 to 2000.
In the case of a non-polymer, the polyhydric alcohol is preferably a 2- to 5-valent alcohol, more preferably a 2- to 3-valent alcohol. The polyhydric alcohol may be saturated or unsaturated, and is preferably saturated. The polyhydric alcohol may be linear, branched or cyclic, and is particularly preferably linear. Specific examples of the polyhydric alcohol include sorbit, glycerin, ethylene glycol, propylene glycol, 1,3-butylene glycol, xylitol, maltitol, maltose, sucrose, fructose, lactitol, erythritol, palatinose, palatinit, glucose, isositol, Examples include trehalose.
As the component (b), among the above, sorbit, glycerin, ethylene glycol, propylene glycol, xylitol, maltose, sucrose, fructose, lactitol, glucose, PEG, and PPG are preferable, and glycerin, ethylene glycol, and PEG are more preferable.
As the component (b), any one type may be used alone, or two or more types may be used in combination.
(B) As for the compounding quantity of a component, 1-30 mass% is preferable with respect to the whole quantity (100 mass%) of compositions for oral cavity, 1-20 mass% is more preferable, 1-10 mass% is further more preferable. Within this range, the effect of the present invention, particularly the stability over time, is excellent. On the other hand, when it is less than 1% by mass, it is difficult to uniformly dissolve the components (c) to (e) in the oil phase, and the production process may be complicated. Conversely, when it exceeds 30 mass%, when a water-insoluble thing is used as (a) component, there exists a possibility that this (a) component may isolate | separate.

[Component (c)]
The component (c) is a (poly) glycerin fatty acid ester. By containing the component (c), the temporal stability of the oral composition and the retention of the active ingredient are improved. This is presumably because the component (c) functions as a solubilizer and a base for the emulsified particles and improves the stability of the emulsified particles.
Examples of the component (c) include those obtained by esterifying higher fatty acids to glycerin or polyglycerin.
The polyglycerin preferably has an average degree of polymerization of 2 to 30, and more preferably 2 to 20. When the average degree of polymerization is within this range, the effect of the present invention is excellent. Moreover, the flavor of the obtained composition for oral cavity is favorable, and palatability increases.
The higher fatty acid is a fatty acid having 8 or more carbon atoms, and the carbon number is preferably 8 to 24, more preferably 8 to 18. When the carbon number is within this range, the effect of the present invention is excellent. Moreover, the flavor of the obtained composition for oral cavity is favorable, and palatability increases.
The fatty acid is preferably linear or branched, and particularly preferably linear. The fatty acid may be either saturated or unsaturated, and is particularly preferably saturated.
In the case of glycerin fatty acid ester, the number of fatty acids ester-bonded to glycerin may be any of 1 to 3.

The following (c1)-(c2) etc. are mentioned as a preferable (c) component.
Ester (c1): Glycerin fatty acid ester in which 1 to 3 fatty acids having 8 to 24 carbon atoms are bonded to glycerin.
Ester (c2): Polyglycerin fatty acid ester in which a fatty acid having 8 to 24 carbon atoms is ester-bonded to polyglycerin having an average degree of polymerization of 2 to 30.
Specific examples of the ester (c1) include glyceryl caproate, glyceryl caprate, glyceryl laurate, glyceryl myristate, glyceryl palmitate, glyceryl stearate, glyceryl tricaprylate, glyceryl tricaprate, glyceryl tricaprylate (caprylate). Is mentioned.
As the ester (c1), trifatty acid glyceryl such as glyceryl tricaprylate, glyceryl tricaprate, glyceryl tri (capryl / capric acid) is preferable.
As ester (c2), monoester, diester or triester is preferable, and monoester is particularly preferable. Examples of the monoester include hexaglycerol monolaurate, decaglycerol monolaurate, hexaglycerol monomyristate, decaglycerol monomyristate and the like.

As the component (c), any one kind may be used alone, or two or more kinds may be used in combination.
In the present invention, the component (c) preferably includes one or both of the esters (c1) and (c2), and particularly preferably includes both. Of these, a combination of tri-fatty acid glyceryl and polyglycerin fatty acid monoester is preferable.
(C) 0.05-20 mass% is preferable with respect to the whole quantity (100 mass%) of compositions for oral cavity, and, as for the compounding quantity of a component, 0.05-10 mass% is more preferable, and 0.05-5 mass. % Is more preferable. Within this range, the effect of the present invention is excellent. On the other hand, when the amount is less than the lower limit of the range, it is difficult to form an emulsion, and there is a possibility that stability with time and retention of active ingredients of the oral composition to be obtained may be lowered. When it mixes exceeding an upper limit, it may become oily and there is a possibility that palatability may worsen.

[Component (d)]
The component (d) is a nonionic surfactant that does not correspond to the (poly) glycerin fatty acid ester. By containing the component (d), the temporal stability of the oral composition and the retention of the active ingredient are improved. This is presumably because the component (d) functions as a solubilizer having a different action from the component (c) and synergistically improves the stability of the emulsified particles.
Examples of the component (d) include fatty acid esters, fatty acid alkanolamides, polyoxyethylene-type ester nonionic surfactants, polyoxyethylene-type ether nonionic surfactants, polyoxyethylene poly, which do not correspond to the component (c). Examples thereof include an oxypropylene (EOPO) block polymer type nonionic surfactant.
Examples of fatty acid esters not corresponding to the component (c) include esters of polyhydric alcohols other than glycerin and polyglycerin or monohydric alcohols and fatty acids.
Examples of the fatty acid in the fatty acid ester or fatty acid alkanolamide include the same fatty acids as those described in the component (c), and the carbon number thereof is preferably 8 to 24, and more preferably 8 to 18.

Specific examples of fatty acid esters not corresponding to component (c) include sucrose fatty acid esters such as sucrose monolaurate and sucrose dilaurate, and sorbitan fatty acid esters.
Examples of fatty acid alkanolamides include lauric acid monoethanolamide, lauric acid diethanolamide, myristic acid monoethanolamide, myristic acid diethanolamide, and oleic acid amide.
Examples of the polyoxyethylene ester nonionic surfactant include polyoxyethylene sorbitan fatty acid esters having an average degree of polymerization of ethylene oxide of 10 to 100 mol, and polyoxyethylene cured castors having an average degree of polymerization of ethylene oxide of 10 to 100 mol. Oil etc. are mentioned.
Examples of the polyoxyethylene ether nonionic surfactant include polyoxyethylene alkyl ether having an average degree of polymerization of ethylene oxide of 6 to 50 mol, and polyoxyethylene alkyl aryl ether having an average degree of polymerization of ethylene oxide of 6 to 50 mol. And polyoxyethylene alkylphenyl ether having an average degree of polymerization of ethylene oxide of 6 to 50 mol.
Examples of the EOPO block polymer type nonionic surfactant include polyoxyethylene polyoxypropylene glycol and polyoxyethylene polyoxypropylene alkyl ether.
Among these, since the flavor of the resulting oral composition is good and the palatability is enhanced, polyoxyethylene-type ester-based nonionic surfactants are preferable, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil Is particularly preferred.
As the component (d), any one kind may be used alone, or two or more kinds may be used in combination.
(D) The compounding quantity of a component is 0.05-10 mass% with respect to the whole quantity (100 mass%) of an oral composition, 0.05-5 mass% is more preferable, 0.05-3 mass % Is more preferable. Within this range, the effect of the present invention, particularly the stability over time, is excellent.

[(E) component]
The component (e) is an anionic surfactant. The component (e) is a cleaning component, and the cleaning power required for the oral composition can be sufficiently obtained by containing the component (e). Moreover, the bactericidal effect is also acquired by containing (e) component.
(E) It does not specifically limit as a component, The thing currently mix | blended with the composition for oral cavity etc. can be utilized. For example, sodium sulfate, sodium myristyl sulfate alkyl sulfate ester salt, lauroyl sarcosine sodium, lauroyl methyl taurine, acyl glutamate sodium, acyl sarcosine sodium acyl amino acid salt, sodium dodecylbenzenesulfonate, α-sulfo fatty acid alkyl ester sodium, Examples thereof include alkyl phosphate ester salts and higher fatty acid sulfonated monoglyceride salts.
Among these, acylamino acid salts are preferable because of their excellent bactericidal effect and foaming properties, and lauroyl sarcosine sodium and lauroylmethyl taurine are particularly preferable.
As the component (e), any one kind may be used alone, or two or more kinds may be used in combination.
(E) 0.01-10 mass% is preferable with respect to the whole quantity (100 mass%) of compositions for oral cavity, and, as for the compounding quantity of a component, 0.01-5 mass% is more preferable. Within this range, the effect of the present invention, particularly the stability over time, is excellent. On the other hand, when the amount is less than the lower limit of the range, there is a possibility that the temporal stability is lowered, and the cleaning effect and the bactericidal effect cannot be sufficiently obtained. When the content exceeds the upper limit, stability with time may be lowered.

In the oil phase, the components (a) to (e) are melted to form a uniform solution.
The method for preparing the oil phase is not particularly limited as long as the components (a) to (e) can be made into a uniform solution.
In the present invention, in particular, after the components (b) to (e) are heated and mixed to a temperature at which the components (b) to (e) are all liquids (for example, about 50 ° C.) and cooled, (A) The method of adding a component and mixing until it becomes a uniform solution is preferable. Thereby, even when mix | blending a fragrance | flavor and a comparatively heat-resistant medicinal agent as (a) component, (a) component can be mix | blended favorably.
Mixing of each component can be implemented using a well-known mixing apparatus. As the mixing device, a low shear type stirring device having stirring blades such as paddle blades and propeller blades is preferable.
The temperature at which the components (b) to (e) are mixed, the temperature at the time of adding the component (a) (cooling temperature) are the melting points of the components (b) to (e) to be used, and the stability of the component (a), respectively. It may be set as appropriate in consideration of the characteristics. For example, the temperature when mixing the components (b) to (e) is preferably 40 ° C to 80 ° C. The cooling temperature is preferably 25 ° C to 40 ° C.
It can be visually confirmed whether or not the mixed solution obtained by mixing the components has become a uniform solution. Specifically, if the appearance of the mixed solution is not phase-separated, it can be determined that the mixed solution is a uniform solution.

  Since the oil phase is excellent in the effects of the present invention, the components (a) to (e) have a value of (c) / [(b) + (d) + (e)] / (a) of 0. It is preferable to contain by the compounding ratio (mass ratio) which becomes in the range of 0.01-4.0. The value of (c) / [(b) + (d) + (e)] / (a) is preferably 0.03 to 3.0, more preferably 0.03 to 1.0, 1.0 is particularly preferred. When the amount is less than the lower limit of the range, the stability over time and the retention of active ingredients may be reduced. If it exceeds the upper limit, the stability over time and the retention of the active ingredient may be lowered, and the oil may become odor and the flavor and palatability may be deteriorated.

<Emulsification process>
Next, the oil phase is put into an aqueous phase to form an emulsion.
Water is used as the aqueous phase.
50-98 mass% is preferable with respect to the whole quantity (100 mass%) of compositions for oral cavity, and, as for the compounding quantity of water, 60-90 mass% is more preferable. Within this range, the palatability and stability of the resulting oral composition are good.
An arbitrary component may be dissolved in the aqueous phase. As this arbitrary component, an appropriate component can be mix | blended according to the use (For example, a liquid dentifrice, a liquid dentifrice, a mouthwash, a mouthwash, etc.). As the component, additives used in the application can be used, and examples thereof include buffers, amino acids, water-soluble dyes, cleaning aids, sweeteners, preservatives (preservatives), pH adjusters and the like.
Buffers include, for example, phthalic acid, phosphoric acid, citric acid, succinic acid, acetic acid, fumaric acid, malic acid and carbonic acid and their potassium, sodium and ammonium salts, ribonucleic acid and its salts, sodium hydroxide, boron Examples thereof include sand and hydrochloric acid hydrogen carbonate.
Examples of amino acids include glycine, DL-alanine, L-alanine, sodium L-aspartate, DL-serine, L-serine, L-isoleucine, L-leucine, sodium L-glutamate and the like.
As the water-soluble dye, a highly safe water-soluble dye such as Blue No. 1, Green No. 3, Yellow No. 4 and Red No. 105 is preferable.
Examples of the cleaning aid include precipitated silica, zirconosilicate, aluminosilicate, calcium phosphate, calcium carbonate, aluminum hydroxide, aluminum oxide and the like.
Sweeteners include, for example, saccharin, sodium saccharin, stevioside, stevia extract, dipotassium glycyrrhizinate, neohesperidihydrochalcone, glycyrrhizin, perilartin, thaumatin, asparatylphenylalanine methyl ester, aspartame, paramethoxycinnamic aldehyde, neohesperidyl dihydroxychalcone, Examples include perilactin, sucrose, fructose, sodium sakuramate, and the like.
Examples of the preservative include sodium benzoate, paraoxybenzoic acid ester, chlorhexidine hydrochloride, chlorhexidine gluconate, lower fatty acid monoglyceride, p-hydroxymethyl benzoic acid, p-hydroxyethyl benzoic acid and the like.
Examples of the pH adjuster include phthalic acid, phosphoric acid, citric acid, succinic acid, acetic acid, fumaric acid, malic acid and carbonic acid, and potassium salts, sodium salts and ammonium salts thereof; ribonucleic acid and salts thereof; sodium hydroxide and the like Is mentioned. 1 type (s) or 2 or more types can be used for a pH adjuster.
The pH at 25 ° C. of the oral composition is generally adjusted to about 5 to 10, preferably about 5 to 8.
The amount of these additives may be in a range that does not impair the effects of the present invention. Usually, the total amount is 0.001 to 1% by mass, preferably 0.01 to 0.5% by mass, based on the total amount (100% by mass) of the oral composition.

The aqueous phase may further contain ethanol. By blending ethanol, a bactericidal effect is obtained and a refreshing feeling is also improved.
However, from the viewpoint of the stability of the composition over time and the prevention of ethanol-derived irritation, the blending amount of ethanol is preferably 30% by mass or less, and 20% by mass or less, with respect to the total amount (100% by mass) of the oral composition. Is more preferable, and 10 mass% or less is still more preferable. The minimum of this compounding quantity is not specifically limited, 0 mass% may be sufficient.

The emulsion can be formed, for example, by introducing the oil phase into the aqueous phase and performing an emulsification operation.
The introduction of the oil phase into the aqueous phase is preferably performed with stirring. The stirring can be carried out using a known mixing device, as in the preparation of the oil phase described above, and a low shear type stirring device is preferred.
The emulsification operation can be performed by a known emulsification method. For example, emulsification can be performed using a high-shearing type stirring device such as a homomixer, an azimuth homo vacuum emulsifier, a nauter mixer, or a high-pressure homogenizer. Among these, it is preferable to use a high-pressure homogenizer. In emulsification with a high-pressure homogenizer, the average particle diameter is adjusted by the difference in shearing force. By using a high-pressure homogenizer, the emulsified particles are atomized and the temporal stability is further improved.
Examples of the high-pressure homogenizer include a microfluidizer (manufactured by Microfluidics International CO), a gorin homogenizer (manufactured by Runny Gorin), and an optimizer (manufactured by Sugino Machine). Further, the present invention is not limited to these models, and any type of high-pressure homogenizer can be used as long as it has a similar mechanism.
The pressure during emulsification (high-pressure emulsification) using a high-pressure homogenizer is usually 30 MPa or more, and 30 to 100 MPa is preferable from the viewpoint of stability.
It is preferable that the oil phase is charged into the aqueous phase and the emulsification operation is performed under a temperature condition of about 25 to 40 ° C. from the viewpoint of the stability of the component (a), particularly the fragrance.

As described above, the oral composition of the present invention can be obtained as an oil-in-water (o / w) type emulsion in which the oil phase is dispersed as emulsified particles in the water phase.
In the emulsion, the average particle size of the emulsified particles is usually about 50 to 5000 nm, and preferably 50 to 3000 nm. The average particle diameter is a value measured by the following measurement method.
Measurement of average particle diameter: Using a light scattering photometer DLS-700 manufactured by Otsuka Electronics Co., Ltd., an emulsion was put into a cell and the average particle diameter at 25 ° C. was measured.
In addition, the component contained in the emulsified particles in the composition for oral cavity (emulsion) is centrifuged at 70,000 rpm for about 30 minutes with respect to the composition, the supernatant is recovered, and liquid chromatography or gas chromatography is performed. It can be detected by tocography.
The composition for oral cavity of the present invention has been conventionally treated in the oral cavity such as liquid dentifrice, liquid dentifrice, mouthwash, mouthwash, etc. (for example, deodorization, scent imparting, sterilization, antibacterial, anti-inflammatory, cleansing, vitamins) It can be used as a liquid treatment agent of any dosage form used for the purpose of supply and the like.

As described above, according to the production method of the present invention, an emulsion-type oral composition can be produced by a simple process, and the resulting oral composition has excellent stability over time and retention of active ingredients. It is.
The reason for the above effect is not clear, but when the oil phase is prepared, other components are dispersed in the component (b), so that it is easy to emulsify when the aqueous phase is charged, and no excessive shear force is applied. However, since it becomes an emulsion, it is considered that the component (a) is stably present in the emulsified particles.

The present invention will be described more specifically with reference to examples. However, the present invention is not limited to these.
[Example 1]
An oral composition having the composition shown in Table 1 was obtained by the following production procedure (hereinafter referred to as production method 1). In Table 1, the unit of the blending amount is mass%. Moreover, the “remainder” of water is an amount such that the total amount of the oral composition is 100% by mass.
The component (b) described in Table 1 (30 g of glycerin, 30 g of propylene glycol, 30 g of PEG (Mw600)) was dissolved in advance by heating (50 ° C.) (c) component (0.75 g of decaglyceryl monomyristate, tri ( (Capryle / capric acid) glyceryl (0.75 g), (d) component (polyoxyethylene (60) hydrogenated castor oil 7.5 g) and (e) component (lauroyl sarcosine sodium 1.5 g) in a 250 mL beaker (made of glass, inner diameter) 70 mm), and mixed with stirring by a propeller blade (blade diameter: 60 mm) at a rotation speed of 500 rpm for 10 minutes. Subsequently, after cooling to 25 ° C., component (a) (fragrance A 3 g, isopropylmethylphenol 0.75 g) is added, and stirring is performed until each component is completely dissolved and becomes a uniform solution (confirmed visually). The oil phase was prepared by mixing.
Separately, 1385.25 g of water and optional components shown in Table 1 (1.5 g of citric acid, 4.5 g of sodium citrate, 4.5 g of benzoic acid) were added to an Ajihomo mixer (HV-M type manufactured by Primix Co., Ltd.). The mixture was added and mixed at a paddle rotation speed of 80 rpm for 10 minutes at room temperature (25 ° C.) to dissolve each optional component.
The prepared oil phase is charged at a rate of 50 g / min, stirred and mixed at a paddle rotation speed of 80 rpm for 10 minutes, and stirred for 45 seconds with a homomixer at a rotation speed of 10,000 rpm for 45 seconds immediately before the end of the stirring. 1500 g of composition was obtained.

The obtained oral composition was centrifuged at 70000 rpm for 30 minutes using a tabletop ultracentrifuge L8-80M manufactured by Beckman Coulter, and the supernatant was collected. The supernatant was analyzed with a gas chromatograph mass spectrometer (GC-MS) (fragrance) and liquid chromatography (LC) (isopropylmethylphenol). As a result, it was confirmed that the supernatant (ie, emulsified particles) contained the component (a) shown in Table 1.
The measurement conditions for GC-MS and LC are shown below.

<GC-MS measurement conditions>
Column: Ultra ALLOY PY-1 (manufactured by Shimadzu Corporation; 0.25 mm × 30 m (0.25 μm))
・ Inlet temperature: 320 ° C
-Detector temperature: 320 ° C
・ Injection volume: 1 μL
Injection method: split injection 20/1
Program: 50 ° C. (0 min) -10 ° C./min-315° C. (10 min)
MS conditions Ionization method: EI

<LC measurement conditions>
Column: KANTO Lighttysil RP-18GP (manufactured by Kanto Chemical Co., Inc .; 5 μm)
-Column temperature: 50 ° C
Mobile phase: methanol / water / phosphoric acid = 1300/700/1
・ Measurement wavelength: UV 285nm
・ Injection volume: 100μL

[Examples 2 to 5]
1500 g of oral composition was obtained by the same procedure (Production Method 1) as in Example 1 except that the types and amounts of the components to be blended were changed to the compositions shown in Table 1.

[Comparative Example 1 (Batch mixing)]
An oral composition having the composition shown in Table 2 was obtained by the following production procedure (hereinafter referred to as production method 2).
Distilled water (244.8 g) was charged into a 400 mL capacity wide-mouthed bottle (mayonnaise bottle). The components shown in Table 2 (components (a) to (e) and optional components) were added individually, and stirring blades (propeller type, diameter 100 mm, shaft diameter × length: 8 × 540 mm) were used. The mixture was stirred at room temperature for 15 minutes at 500 rpm to obtain 400 g of an oral composition. Among the components described above, the component (c), the component (d), and the component (e) were each previously melted at 50 ° C. and added. Moreover, (a) component was added after mixing other components and cooling to room temperature (25 degreeC).

[Comparative Example 2 (with emulsion)]
An oral composition having the composition shown in Table 2 was obtained by the following production procedure (hereinafter referred to as production method 3).
First, an emulsion B having the following composition was prepared by the following procedure.
・ Decaglyceryl monomyristate 9.9% by mass
・ Tri (capryl / capric acid) glyceryl 49.5% by mass
・ Glycerin 14.85 mass%
・ Isopropylmethylphenol 1% by mass
-Water 24.75 mass%.
A predetermined amount of decaglyceryl monomyristate, glycerin and half amount of water melted at 50 ° C. and half amount of water were added to an Ajihomo mixer (HV-M type manufactured by Primix Co., Ltd.), and 10 at a paddle rotation speed of 80 rpm. Dissolved and mixed at room temperature for minutes. Thereafter, tri (capryl / capric acid) glyceryl was added, and the mixture was stirred and mixed at room temperature for 10 minutes at a paddle rotation speed of 80 rpm, and further stirred at a rotation speed of 10,000 rpm with a homomixer for 20 seconds immediately before the end of the stirring. Emulsion B was prepared by adding the remaining water.

Next, 241.8 g of distilled water was charged into a 400 mL capacity wide-mouth bottle (mayonnaise bottle). Among the components shown in Table 2, components other than the emulsion B (components (a), (b), (d), optional components and ethanol) were added individually so as to have the compositions shown in Table 2. did. At this time, among the above components, the component (b) and the component (d) were previously melted at 50 ° C. and added. Moreover, (a) component was added after mixing other components and cooling to room temperature (25 degreeC).
Emulsion B was then added and stirred using a stirring blade (propeller type, diameter 100 mm, shaft diameter x length: 8 x 540 mm) at 500 rpm for 15 minutes at room temperature to obtain an oral composition. It was.

[Comparative Examples 3 to 5]
1500 g of oral composition was obtained by the same procedure (Production Method 1) as in Example 1 except that the types and amounts of the components to be blended were changed to the compositions shown in Table 2.

The following evaluation was performed about the obtained composition for oral cavity. The results are shown in Tables 1-2.
[Storage stability]
The appearance of the oral composition after storage at 5 ° C. or 50 ° C. for 1 month was visually evaluated according to the following criteria. An evaluation result of “◎” or “○” was determined to be acceptable.
(Evaluation criteria)
A: There is no separation or precipitation, and it is uniform.
○: Slight precipitation is observed but uniform.
Δ: Although it is a small amount, clear separation and precipitation are observed, and it is non-uniform.
X: Considerable separation and precipitation are observed, and it is non-uniform.

[Isopropylmethylphenol remaining rate]
10 mL of oral composition was contained in the mouth, rinsed for 30 seconds, and then exhaled. The amount (mL) of the discharge liquid and the concentration of isopropylmethylphenol contained in the discharge liquid were measured by LC. The LC measurement conditions were the same as in Example 1.
From the isopropylmethylphenol concentration (A1) in the oral composition immediately after preparation, the isopropylmethylphenol concentration (A2) in the discharge liquid obtained by measurement, and the discharge liquid amount (B), the following formula is used to calculate isopropylmethylphenol. The residual rate (%) in the oral cavity was calculated.
Residual rate (%) = A2 × 100 / A1 / B × 100

[Flavor persistence]
Ten panelists included 10 mL of each oral composition in their mouths, and after spitting for 30 seconds, they exhaled.
After discharge, the time that the flavor lasted (time from immediately after discharge until the flavor disappeared) was evaluated, and the average duration of 10 panelists was determined. From the duration, flavor sustainability was evaluated according to the following criteria. An evaluation result of “◎” or “○” was determined to be acceptable.
(Evaluation criteria)
(Double-circle): The duration of a flavor is 15 minutes or more.
○: The flavor duration is 10 minutes or more and less than 15 minutes.
(Triangle | delta): The duration of a flavor is 5 minutes or more and less than 10 minutes.
X: The flavor duration is less than 5 minutes.

As shown in the above results, in Examples 1 to 5, the emulsion type oral cavity is produced by a simple manufacturing method in which the oil phase is mixed into the aqueous phase by mixing the components (a) to (e). A composition was obtained. In addition, the oral composition had good evaluation results for all of 5 ° C. stability over time, 50 ° C. stability over time, isopropylmethylphenol residual rate and flavor sustainability. In particular, the evaluation results of Examples 1 to 4 having a value of c / (b + d + e) / a of 4.0 or less were good.
On the other hand, the composition for oral cavity of Comparative Example 1 in which all ingredients were mixed at once, although having the same composition as Example 2, stability over time, retention of active ingredients (residual ratio of isopropylmethylphenol, sustained flavor) Both were bad.
The comparative example 2 which mix | blended the emulsion B prepared separately took the process, and the flavor sustainability of the obtained oral composition was also unsatisfactory.
Comparative Example 3 in which component (c) was not blended, Comparative Example 4 in which component (b) was not blended, and Comparative Example 4 in which components (b) to (e) were not blended were all poor.

The raw materials used in Examples 1-5 and Comparative Examples 1-5 are shown below.
・ Isopropyl methylphenol: Osaka Kasei Co., Ltd.
・ Glycerin: manufactured by Sakamoto Pharmaceutical Co., Ltd.
-Propylene glycol: manufactured by Asahi Denka Co., Ltd.
・ Decaglyceryl monomyristate: manufactured by Nikko Chemicals.
Tri (capryl / capric acid) glyceryl: manufactured by Nippon Emulsion Co., Ltd.
Polyoxyethylene (60) hydrogenated castor oil: manufactured by Nikko Chemicals.
PEG (Mw600): Mw600 polyethylene glycol, “PEG # 600” manufactured by Lion Corporation.
・ Lauroyl methyl taurine sodium: manufactured by Nikko Chemicals.
・ Lauroyl sarcosine sodium: manufactured by Nikko Chemicals.
Citric acid: manufactured by Fuso Chemical.
・ Sodium citrate: manufactured by Fuso Chemical.
・ Saccharin sodium: manufactured by Toyo Kasei Chemical Co., Ltd.
・ Sodium benzoate: manufactured by Nissei Bairis.
-Ethanol: Purity 95% by mass or more, manufactured by Nippon Alcohol Sales Company.
Fragrance A: A fragrance composition having a composition (unit: mass%) shown in Table 3 below (solubility in water: 1% or less).

[Examples 6 to 12]
An oral composition was obtained in the same manner as in Example 1 except that the types and amounts of the components to be blended were changed to the compositions shown in Tables 4 to 10, respectively.
Among these oral compositions, the oral compositions of Examples 6 to 8 are suitable as liquid dentifrices. The oral compositions of Examples 9 to 11 are suitable as mouthwashes. The oral composition of Example 12 is suitable as a mouthwash.

Claims (2)

  (A) an active ingredient selected from a fragrance and a medicinal agent, (b) a polyhydric alcohol, (c) a (poly) glycerin fatty acid ester, and (d) a nonionic surfactant that does not fall under the (poly) glycerin fatty acid ester (E) The manufacturing method of the composition for oral cavity characterized by using the oil phase formed by mixing an anionic surfactant in an aqueous phase, and setting it as an emulsion.   In the oil phase, the components (a) to (e) are in the range of (c) / [(b) + (d) + (e)] / (a) in the range of 0.01 to 4.0. The manufacturing method of the composition for oral cavity of Claim 1 contained by the mixture ratio (mass ratio) which becomes.